Member Info for Basser1

Unlike the Thames, all t-rds here have been filtered. Bliss. Strongly recommended you all do the same.

There are big conference events coming up soon and we should assume that there will be more interested parties once they have seen the overwhelming positive phase1 data. Things which seem set in stone at the moment may change the more interest there is. A number of scenario’s might appear.

Unfortunately the unequal treatment of buys and sells has prevailed for far too long.

It is possibly why AIM is being subject to a current think tank review to look at better support for budding tech companies and improving valuations which of course is good for UK Growth.

£13,372. Wow and 3.57% down. Two days ago buys were over 100,000 shares bought and didn’t move. There are taking the pss.

Oxmill - if needed.

I’m with Laz. Always bullish and I am happy to sit, be patient after a very good RNS emphasising Best in Class for Autoimmune with at least four potential treatments covering psoriasis, Rheumatoid Arthritis, Lupus and Bowel diseases. If you cannot be excited and patient about that, then you need to get help!

Been rumblings for some time re AIM not doing enough to support tech companies. Looks like there may be some changes given the current focus on Growth.

Let’s not forget the extensive Patent coverage. That on its own will be very valuable.

Interested buyers would have seen the potential of the current results and claim of best in class for 1801. They will have to shell out a considerable sum, so I can understand why they want to be satisfied re effects of longer term toxicity. It seems that HNWI and institution have been given assurance so I think we can move forward with some confidence in the outcome.GLA Happy Days!

Parker refers to “a number of autoimmune diseases”. That’s likely to be three or more? Would that suggest the price of SDC1801, if best in class to be around 3-4 Billion?

As JAKis block cytokines that are involved in multiple pathways, they may have multi-system impacts. However, given the differences in inhibitory potency of individual JAKis for each JAK isoform, each molecule has a unique clinical toxicity profile, as supported by extensive pre-clinical and clinical findings. Long-term extension (LTE) and other post-marketing studies remain necessary to evaluate JAKi safety in the treatment of chronic inflammatory conditions, particularly considering that these diseases themselves are often associated with increased risk [2]. Recently raised concerns include increased risk of cardiovascular and thromboembolic events in certain higher-risk patient populations, highlighting the potential ramifications of JAK/STAT pathway inhibition, particularly with pan- or multi-JAKis [2]. However, there is no robust compelling evidence to date supporting that the mechanism of action of JAKis would be the reason for a potential increased risk for cardiovascular events or malignancies. Moreover, JAKis may decrease the risk of these events by decreasing disease activity, since chronic inflammation is a well-known independent risk factor for these

Https://www.google.com/url?q=https://academic.oup.com/rheumatology/article/63/2/298/7251024&sa=U&sqi=2&ved=2ahUKEwjT3cuLoYuJAxWxwAIHHQbBDM8QFnoECDkQAQ&usg=AOvVaw1anIcbJpUFubJ83f6nTwhw

Very true. Aim is a destroyer of company values. How they got away with today’s buys and sell ratio is beyond belief.

Even if the results are top notch, do you think we will make 0.40p? Ha ha.

Aber - had the same thought. But the chance of both of us getting it right with our record does not bode well!

Think they were all buys

6 Trades delayed?

Psoriasis market is 27.20 billion dollars in 2024 and is expected to grow to 57.68 billion dollars by 2032. And Sareum is talking about “other autoimmune diseases” as well! Think it’s a big mistake to be talking down the expectations of a sizeable deal. When has there ever been a treatment that may be capable of treating a number of ailments each worth billions of dollars!

Note - ‘’Psoriasis and other Autoimmune diseases.” Sounds exciting.

SDC 1801 “new therapeutic for a range of Autoimmune diseases”. Must be confident of current results?